[1] Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2018, 68(6):394-424. [2] Moradpoor R, Gharebaghian A, Shahi F, et al. Identification and validation of stage-associated PBMC biomarkers in breast cancer using MS-based proteomics. Front Oncol, 2020, 10:1101. [3] Barrett T, Troup DB, Wilhite SE, et al. Ncbi geo: archive for high-throughput functional genomic data. Nucleic Acids Res, 2009, 37(Database issue):D885-890. [4] Shi M, Chen MS, Sekar K, et al. A blood-based three-gene signature for the non-invasive detection of early human hepatocellular carcinoma. Eur J Cancer, 2014, 50(5):928-936. [5] Franceschini A, Szklarczyk D, Frankild S, et al. String v9.1: protein-protein interaction networks, with increased coverage and integration. Nucleic Acids Res, 2013, 41(Database issue):D808-815. [6] Kohl M, Wiese S, Warscheid B. Cytoscape: software for visualization and analysis of biological networks. Methods Mol Biol, 2011, 696: 291-303. [7] Tang Z, Li C, Kang B, et al. Gepia: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res, 2017, 45(1):W98-W102. [8] Ashburner M, Ball CA, Blake JA, et al. Gene ontology: tool for the unification of biology. the gene ontology consortium. Nat Genet, 2000, 25(1): 25-29. [9] Ogata H, Goto S, Sato K, et al. Kegg: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res, 1999, 27(1): 29-34. [10] 雷海科, 李小升, 赵玉兰, 等. 原发性肝癌患者生存预后及影响因素分析(附3106例报告). 中华消化外科杂志, 2020, 19(2):179-184. [11] Singh AK, Kumar R, Pandey AK. Hepatocellular carcinoma: causes, mechanism of progression and biomarkers. Curr Chem Genom Transl Med, 2018, 12:9-26. [12] 王翠晓, 高静. 血清高尔基蛋白73、甲胎蛋白异质体3、甲胎蛋白和α-L-岩藻糖苷酶水平诊断原发性肝癌的效能分析. 实用肝脏病杂志, 2019, 22(1):118-121. [13] He XQ, Zhang YF, Yu JJ, et al. High expression of G-protein signaling modulator 2 in hepatocellular carcinoma facilitates tumor growth and metastasis by activating the PI3K/AKT signaling pathway. Tumour Biol, 2017, 39(3):1010428317695971. [14] Deng M, Zhang Z, Liu B, et al. Localization of GPSM2 in the nucleus of invasive breast cancer cells indicates a poor prognosis. Front Oncol, 2020, 10:227. [15] Deng M, Liu B, Zhang Z, et al. Knockdown of G-protein-signaling modulator 2 promotes metastasis of non-small-cell lung cancer by inducing the expression of snail. Cancer Sci, 2020, 111(9):3210-3221. [16] Shukla S, Fisher SA. Tra2beta as a novel mediator of vascular smooth muscle diversification. Circ Res, 2008, 103(5): 485-492. [17] Fischer DC, Noack K, Runnebaum IB, et al. Expression of splicing factors in human ovarian cancer. Oncol Rep, 2004, 11(5):1085-1090. [18] Diao Y, Wu D, Dai Z, et al. Prognostic value of transformer 2beta expression in prostate cancer. Int J Clin Exp Pathol, 2015, 8(6):6967-6973. [19] Gabriel B, Hausen AZ, Bouda J, et al. Significance of nuclear hTra2-beta1 expression in cervical cancer. Acta Obstet Gynecol Scand, 2009, 88(2):216-221. [20] Watermann DO, Tang Y, Hausen AZ, et al. Splicing factor Tra2-beta1 is specifically induced in breast cancer and regulates alternative splicing of the CD44 gene. Cancer Res, 2006, 66(9): 4774-4780. |